A phase I clinical trial combining the HDAC inhibitor panobinostat with the mTOR inhibitor everolimus is currently enrolling patients with non-Hodgkin's lymphoma (NHL) and HL. This evidence concerns the gene MTOR and Hodgkins lymphoma.